DexCom (DXCM) Expected to Announce Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM - Get Free Report) is projected to announce its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of $0.33 per share and revenue of $1.02 billion for the quarter.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Trading Up 0.2 %

Shares of DXCM traded up $0.12 during mid-day trading on Tuesday, reaching $71.30. The stock had a trading volume of 2,331,956 shares, compared to its average volume of 4,207,841. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom has a 52-week low of $57.52 and a 52-week high of $132.26. The business's fifty day moving average is $72.35 and its 200 day moving average is $76.70. The firm has a market cap of $27.96 billion, a price-to-earnings ratio of 49.86, a P/E/G ratio of 2.30 and a beta of 1.50.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 105,009 shares of company stock worth $8,044,178. Corporate insiders own 0.32% of the company's stock.

Hedge Funds Weigh In On DexCom

A hedge fund recently raised its stake in DexCom stock. Brighton Jones LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 257.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,582 shares of the medical device company's stock after acquiring an additional 11,946 shares during the period. Brighton Jones LLC's holdings in DexCom were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on DXCM shares. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Cfra Research raised shares of DexCom to a "hold" rating in a report on Friday, March 21st. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and upped their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $99.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.